z-logo
open-access-imgOpen Access
Completely Resected N0 Non-Small Cell Lung Cancer: Prognostic Factors Affecting Long-Term Survival
Author(s) -
Apichat Tantraworasin,
Somcharoen Saeteng,
Nirush Lertprasertsuke,
Nuttapon Arayawudhikule,
Choosak Kasemsarn,
Jayanton Patumad
Publication year - 2013
Publication title -
isrn surgery
Language(s) - English
Resource type - Journals
eISSN - 2090-5793
pISSN - 2090-5785
DOI - 10.1155/2013/175304
Subject(s) - medicine , oncology , metastasis , brain metastasis , stage (stratigraphy) , proportional hazards model , lung cancer , pathological , hazard ratio , survival rate , survival analysis , necrosis , primary tumor , cancer , biology , confidence interval , paleontology
Background. Although early stage non-small cell lung cancer (NSCLC) has an excellent outcome and correlated with good long-term survival, up to 15 percent of patients still relapse postoperatively and die. This study is conducted to identify prognostic factors that may affect the long-term survival in completely resected N0 NSCLC. Methods. Medical records of 124 patients with completely resected N0 NSCLC were retrospectively reviewed. Prognostic factors affecting long-term survival were analyzed by the Kaplan-Meier method and Cox proportional hazards analysis. Results. Overall five-year survival rate was 48 percent. Multivariable analysis revealed stage of disease, tumor necrosis, tumor recurrence, brain metastasis, adrenal metastases, and skin metastases as significant prognostic factors affecting long-term survival. The hazard ratio (HR) of tumor necrosis, tumor recurrence, brain metastasis, adrenal metastases, and skin metastases was 2.0, 2.3, 7.6, 4.1, and 8.3, respectively, and all P values were less than 0.001. Conclusions . Our study shows stage of disease, tumor necrosis, tumor recurrence, brain metastasis, adrenal metastasis, and skin metastasis as the independent prognostic factors of long-term survival in pathological N0 NSCLC. Early stage NSCLC patients without nodal involvement or presented with tumor necrosis should benefit from adjuvant chemotherapy, and sites of metastasis could predict the long-term survival as described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom